Vimarsana
Biggest News Aggregation in the World

Page 3 - Timothy Ko News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Timothy Ko. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Timothy Ko Today - Breaking & Trending Today

Entheon Biomedical Corp.: Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US - Vimarsana News

Entheon Biomedical Corp.: Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US

HaluGen Life Sciences' test evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy Vancouver, British Columbia--(Newsfile Corp. - June 10, 2021) -

Entheon Biomedical Corp.: Entheon Biomedical Lists on OTCQB Venture Market - Vimarsana News

Entheon Biomedical Corp.: Entheon Biomedical Lists on OTCQB Venture Market

Entheon Biomedical Corp.: Entheon Biomedical Lists on OTCQB Venture Market Entheon" or the " Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has been approved for trading on the OTCQB Venture Market ("OTCQB") effective May 5, 2021. "We are thrilled to be up-listing on to the OTCQB, which will allow for greater engagement with our U.S. investor base. As we advance our DMT addiction therapy program toward human trials, continue R&D on our diagnostic and patient-monitoring platform, and scale up commercial availabi...

Mind Cure Health (MCURF), MYDECINE INNOV GRP by MYDECINE INNOVATIONS GROUP INC. (MYCOF) - Psyched: Entheon Launches Psychedelics Genetic Test, Mydecine Unveils Psychedelic Drug Candidates, California Bill Passes Senate Committee - Vimarsana News

Mind Cure Health (MCURF), MYDECINE INNOV GRP by MYDECINE INNOVATIONS GROUP INC. (MYCOF) - Psyched: Entheon Launches Psychedelics Genetic Test, Mydecine Unveils Psychedelic Drug Candidates, California Bill Passes Senate Committee

The candidates are:  MYCO – 001: a form of pure psilocybin derived from natural fungal sources, targeted to be used at mid-to-late-stage clinical trials. MYCO – 002: an empathogen with similar effects to MDMA that could have an improved safety profile. MYCO – 003: a psilocybin-based formula that could diminish the possibility of bad experiences by reducing patient anxiety. MYCO – 004: a hallucinogen delivered transdermally, offering precision dosing and long-term compound stability. The claims presented for these compounds need to be proven in clinical trials and via further research...

Entheon Biomedical (ENTBF) - Entheon Launches Psychedelics Pre-Screening Genetic Test - Vimarsana News

Entheon Biomedical (ENTBF) - Entheon Launches Psychedelics Pre-Screening Genetic Test

HaluGen Life Sciences Inc. The test will serve as a pre-screening platform for patients looking into psychedelics-assisted psychotherapy, giving out “genetic, personal and familial insights” to improve patient care and reduce possible risks associated with the therapy. "For Entheon, the launch of this product also represents our first revenue stream as we work to develop commercial partnerships for the mass sale of the test,” said CEO Timothy Ko. The company said the test is now available for sale in Canada, and expects to offer availability in the U.S. in coming months. How Does It Wo...

Entheon Biomedical Corp. Launches HaluGen's Psychedelics Genetic Test - Vimarsana News

Entheon Biomedical Corp. Launches HaluGen's Psychedelics Genetic Test

Entheon Biomedical Corp. Launches HaluGen's Psychedelics Genetic Test HaluGen's DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy Vancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry's first Psychedelics Genetic Test Kit, developed by wholly-owned subsidiary, HaluGen Life Sciences Inc. ("HaluGen"), and that it is...